Buzz Health President Joseph Kleiman discusses how TrumpRx is reshaping drug price transparency, highlighting the benefits of early price visibility for consumers alongside the operational challenges of fluctuating costs, consistency and potential.
Joseph Kleiman
Advertisement
Drawing from his work across prescription pricing and fulfillment infrastructure, Kleinman can offer insight into how alternative pricing models interact with prescribing workflows, coverage rules, and pharmacy operations, and why backend execution ultimately determines whether transparency goals are achieved
Articles by Joseph Kleiman
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Pharma Mergers and Acquisitions Roundup: Novo Nordisk Enters $2.1 Billion Partnership with Vivtex, GSK Enters $950 Million Acquisition Agreement with 35Pharma Inc.
2
FDA Approves Dupixent as First Treatment for Allergic Fungal Rhinosinusitis in Adults and Children
3
Competitive Simulation – Defining Strategy Through Lived Experiences
4
FDA Grants Full Approval to Braftovi Combination for First-Line BRAF V600E–Mutant Metastatic Colorectal Cancer
5